GeoVax Labs price target adjusted to $8 post reverse split at H.C. Wainwright

H.C. Wainwright notes that GeoVax Labs announced it received a Rapid Response Partnership Vehicle award of approximately $24.3M from the Biomedical Advanced Research and Development Authority, or BARDA, to advance development of GEO-CM04S1. The firm, which is positive on the news of the direct award to GeoVax, believes 04S1’s potential to be a universal vaccine approach is underappreciated, keeps a Buy rating on GeoVax and established a post-reverse-stock-split price target of $8. Its prior price target of $8, set prior to GeoVax’s 1-for-15 reverse split, was equivalent to $120 on the post-reverse-split shares, the analyst noted.